Business Context and Reporting Period
This Form 8-K was filed by Recursion Pharmaceuticals, Inc. on April 11, 2022. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol RXRX. The filing reports a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. As an 8-K reporting a specific event, it does not provide a clear value for any financial metrics.
Material Changes
The material change reported is a regulatory milestone:
- FDA Fast Track Designation: The U.S. Food and Drug Administration (FDA) granted Fast Track designation for the company's candidate REC-4881.
- Indication: The designation is for the potential treatment of Familial Adenomatous Polyposis (FAP) in patients who have previously undergone a colectomy or proctocolectomy.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) regarding the FDA designation but does not provide updated financial guidance, management commentary on future performance, or specific risk factors within the text of this report. The Fast Track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the Fast Track designation criteria.
- Confirm the current clinical development status of REC-4881 for FAP.
- Review the company's most recent 10-K or 10-Q for financial health, cash runway, and debt obligations, as this 8-K contains no such data.
- Monitor future filings for updates on the regulatory timeline for REC-4881.